These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23603069)

  • 41. Enzyme replacement therapy in severe adult-onset glycogen storage disease type II.
    Ravaglia S; Danesino C; Pichiecchio A; Repetto A; Poloni GU; Rossi M; Fratino P; Moglia A; Costa A
    Adv Ther; 2008 Aug; 25(8):820-9. PubMed ID: 18704279
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Pompe disease treated with enzyme replacement therapy in pregnancy].
    Grosz Z; Várdi KV; Molnár JM
    Ideggyogy Sz; 2020 Sep; 73(9-10):339-344. PubMed ID: 33035415
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study.
    Güngör D; Kruijshaar ME; Plug I; D'Agostino RB; Hagemans ML; van Doorn PA; Reuser AJ; van der Ploeg AT
    Orphanet J Rare Dis; 2013 Mar; 8():49. PubMed ID: 23531252
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of long term enzyme replacement therapy in late onset Pompe disease: A single-centre experience.
    Papadimas GK; Anagnostopoulos C; Xirou S; Michelakakis H; Terzis G; Mavridou I; Kararizou E; Papadopoulos C
    Neuromuscul Disord; 2021 Feb; 31(2):91-100. PubMed ID: 33451932
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Both type 1 and type 2a muscle fibers can respond to enzyme therapy in Pompe disease.
    Drost MR; Schaart G; van Dijk P; van Capelle CI; van der Vusse GJ; Delhaas T; van der Ploeg AT; Reuser AJ
    Muscle Nerve; 2008 Feb; 37(2):251-5. PubMed ID: 17894362
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease.
    Koeberl DD; Austin S; Case LE; Smith EC; Buckley AF; Young SP; Bali D; Kishnani PS
    FASEB J; 2014 May; 28(5):2171-6. PubMed ID: 24443373
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Making diagnosis of Pompe disease at a presymptomatic stage: to treat or not to treat?
    Laloui K; Wary C; Carlier RY; Hogrel JY; Caillaud C; Laforêt P
    Neurology; 2011 Aug; 77(6):594-5. PubMed ID: 21753173
    [No Abstract]   [Full Text] [Related]  

  • 48. Pompe disease in Austria: clinical, genetic and epidemiological aspects.
    Löscher WN; Huemer M; Stulnig TM; Simschitz P; Iglseder S; Eggers C; Moser H; Möslinger D; Freilinger M; Lagler F; Grinzinger S; Reichhardt M; Bittner RE; Schmidt WM; Lex U; Brunner-Krainz M; Quasthoff S; Wanschitz JV
    J Neurol; 2018 Jan; 265(1):159-164. PubMed ID: 29181627
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation.
    Desai AK; Walters CK; Cope HL; Kazi ZB; DeArmey SM; Kishnani PS
    Mol Genet Metab; 2018 Feb; 123(2):92-96. PubMed ID: 29289479
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quantification of muscle pathology in infantile Pompe disease.
    Schänzer A; Kaiser AK; Mühlfeld C; Kulessa M; Paulus W; von Pein H; Rohrbach M; Viergutz L; Mengel E; Marquardt T; Neubauer B; Acker T; Hahn A
    Neuromuscul Disord; 2017 Feb; 27(2):141-152. PubMed ID: 27927596
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and efficacy of exercise training in adults with Pompe disease: evalution of endurance, muscle strength and core stability before and after a 12 week training program.
    van den Berg LE; Favejee MM; Wens SC; Kruijshaar ME; Praet SF; Reuser AJ; Bussmann JB; van Doorn PA; van der Ploeg AT
    Orphanet J Rare Dis; 2015 Jul; 10():87. PubMed ID: 26187632
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients.
    van der Meijden JC; Kruijshaar ME; Rizopoulos D; van Doorn PA; van der Beek NAME; van der Ploeg AT
    Orphanet J Rare Dis; 2018 May; 13(1):82. PubMed ID: 29788986
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pain in adult patients with Pompe disease: a cross-sectional survey.
    Güngör D; Schober AK; Kruijshaar ME; Plug I; Karabul N; Deschauer M; van Doorn PA; van der Ploeg AT; Schoser B; Hanisch F
    Mol Genet Metab; 2013 Aug; 109(4):371-6. PubMed ID: 23849261
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques.
    Young SP; Piraud M; Goldstein JL; Zhang H; Rehder C; Laforet P; Kishnani PS; Millington DS; Bashir MR; Bali DS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):50-8. PubMed ID: 22252961
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term effects of enzyme replacement therapy in an elderly cohort of late-onset Pompe disease.
    Winkler M; von Landenberg C; Kuchenbecker K; Reimann J; Kornblum C
    Neuromuscul Disord; 2022 Mar; 32(3):195-205. PubMed ID: 35120758
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Investigation on acute effects of enzyme replacement therapy and influence of clinical severity on physiological variables related to exercise tolerance in patients with late onset Pompe disease.
    Sechi A; Salvadego D; Da Ponte A; Bertin N; Dardis A; Cattarossi S; Devigili G; Reccardini F; Bembi B; Grassi B
    Neuromuscul Disord; 2017 Jun; 27(6):542-549. PubMed ID: 28433478
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study.
    Anderson LJ; Henley W; Wyatt KM; Nikolaou V; Waldek S; Hughes DA; Lachmann RH; Logan S
    J Inherit Metab Dis; 2014 Nov; 37(6):945-52. PubMed ID: 24906254
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Enzyme Replacement Therapy for Pompe Disease: The Long-Term Efficacy and Limitation].
    Fukuda T; Sugie H
    Brain Nerve; 2015 Sep; 67(9):1091-8. PubMed ID: 26329149
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients.
    Bernstein DL; Bialer MG; Mehta L; Desnick RJ
    Mol Genet Metab; 2010; 101(2-3):130-3. PubMed ID: 20638881
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment with enzyme replacement therapy during pregnancy in a patient with Pompe disease.
    Holbeck-Brendel M; Poulsen BK
    Neuromuscul Disord; 2017 Oct; 27(10):956-958. PubMed ID: 28735900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.